A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 29 Jul 2014
Accessed on 23 Sep 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01047319.